



Cite this: *J. Mater. Chem. B*, 2024, 12, 275

Correction: Mitochondria-targeting nanozyme alleviating temporomandibular joint pain by inhibiting the TNF α /NF- κ B/NEAT1 pathway

Qian Bai,^a Yaoyao Zhou,^a Xiaona Cui,^{ab} Haichao Si,^e Tingting Wu,^a Abdul Nasir,^{ac} Heng Ma,^{ac} Junyue Xing,^d Yingying Wang,^d Xiaolei Cheng,^d Xiaojun Liu,^{*b} Shaoyan Qi,^{*b} Zhisong Li^c and Hao Tang^{*d}

DOI: 10.1039/d3tb90183a

rsc.li/materials-b

Correction for 'Mitochondria-targeting nanozyme alleviating temporomandibular joint pain by inhibiting the TNF α /NF- κ B/NEAT1 pathway' by Qian Bai et al., *J. Mater. Chem. B*, 2023, <https://doi.org/10.1039/d3tb00929g>.

The authors regret the error in Fig. 6 due to a figure compilation error. The corrected Fig. 6 is shown below.

^a Medical Research Center, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China

^b Department of Critical Care Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China. E-mail: liuxiaojunzzu@163.com, qishaoyan1970@163.com

^c Department of Anesthesiology and Perioperative Medicine, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

^d National Health Commission Key Laboratory of Cardiovascular Regenerative Medicine, Heart Center of Henan Provincial People's Hospital, Central China Fuwai Hospital of Zhengzhou University, Fuwai Central China Cardiovascular Hospital & Central China Branch of National Center for Cardiovascular Diseases, Zhengzhou, Henan, 451464, China. E-mail: tangpku_zzuhao@zzu.edu.cn

^e Department of Anesthesiology, Nanyang Central Hospital, Nanyang, Henan, China






Fig. 6 Intravenous Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated the TNF α /NF- κ B/Neat1 pathways in a mouse TMD pain model. (A) Single i.v. Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated Neat1 in Sp5C in mouse TMD pain model after 3 d; $^{**}P < 0.01$; $^{****}P < 0.0001$, two-way ANOVA, $N = 18$. (B) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA injection downregulated p-p65 in Sp5C in mouse TMD pain model after 3 d; $^{****}P < 0.0001$ vs. CFA + vehicle; two-way ANOVA, $N = 39$. (C) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA/saline injection did not alter p65 expression in Sp5C after 3 d; $^{ns}P > 0.05$, $N = 27$. (D) Single i.v. Mito-Ru MOF injection 30 min after TMJ CFA injection counteracted the increase in p-p65 immunofluorescence intensity in Sp5C in mouse TMD pain model after 3 d (scale bar = 400 μ m). (E) Statistical analysis of data in (D) $^{****}P < 0.0001$ vs. CFA + vehicle group, $N = 3$, two-way ANOVA. (F) Intra-Sp5C NF- κ B injection in downregulated Neat1 in naive mice; $^{**}P < 0.01$ vs. Scramble control, $N = 5$; t -test. (G) Single i.v. Mito-Ru MOF injection 30 min after intra-TMJ CFA injection downregulated TNF- α in Sp5C in mouse TMD pain model after 3 d; $^{***}P < 0.001$ vs. CFA + vehicle, $N = 4$; two-way ANOVA.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

